MIRI brandmark


Tranexamic acid to Reduce Infection after Gastrointestinal Surgery


Tranexamic acid is a lysine analogue that acts by blocking the lysine‐dependent production of plasmin and resultant fibrinolysis. Plasmin has direct effects on immune function and inflammation, and we have compelling laboratory and clinical evidence demonstrating tranexamic acid may reduce infection risk in surgery.


This multicentre, pragmatic, double‐blind, randomised clinical trial will compare the incidence of surgical site infection and red cell transfusion requirements after IV tranexamic acid and placebo in patients undergoing gastrointestinal surgery


Trial Length & Recruitment Aims

Five years, aiming to recruit 50 patients.

Share This Post

More Research Profiles